{"id":33103,"date":"2025-05-09T14:44:20","date_gmt":"2025-05-09T06:44:20","guid":{"rendered":"https:\/\/flcube.com\/?p=33103"},"modified":"2025-05-09T14:44:21","modified_gmt":"2025-05-09T06:44:21","slug":"zai-lab-reports-q1-2025-revenue-growth-and-pipeline-progress","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33103","title":{"rendered":"Zai Lab Reports Q1 2025 Revenue Growth and Pipeline Progress"},"content":{"rendered":"\n<p>China-based biotech Zai Lab Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/ZLAB:NASDAQ\">NASDAQ: ZLAB<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/9688:HKG\">HKG: 9688<\/a>) released its Q1 2025 financial report alongside recent product highlights and corporate updates. Total revenues for the quarter stood at USD 106.5 million, marking a 22% year-on-year (YOY) increase at constant exchange rates. The company also reported a significant improvement in operating loss, which declined by 20% YOY to USD 56.3 million, remaining on track to achieve profitability by the fourth quarter of 2025. Research and development (R&amp;D) expenses were USD 60.7 million. As of March 31, 2025, cash and cash equivalents, short-term investments, and current restricted cash totaled USD 857.3 million.<\/p>\n\n\n\n<p><strong>Product Performance<\/strong><br>Net product revenue for Q1 2025 was USD 105.7 million, up 21% YOY. Vyvgart (efgartigimod alfa IV infusion) and Vyvgart Hytrulo (efgartigimod alfa subcutaneous injection) generated USD 18.1 million, driven by increased sales volume and the inclusion of its new myasthenia gravis indication in the updated National Reimbursement Drug List (NRDL). Market coverage and penetration for these products continued to expand. Zejula (niraparib) delivered USD 49.5 million in sales, maintaining its leadership as the top PARP inhibitor for ovarian cancer in China\u2019s hospital market. Nuzyra (omadacycline) contributed USD 15.1 million.<\/p>\n\n\n\n<p><strong>Pipeline Development<\/strong><br>In terms of pipeline progress, ZL-1310, a DLL3-targeting antibody-drug conjugate (ADC), is advancing rapidly with data in extensive-stage small cell lung cancer (ES-SCLC) expected soon. Registrational clinical studies for ES-SCLC are planned to commence in the second half of 2025. ZL-6201 (LRRC15 ADC) and ZL-1222 (PD-1\/IL-12 bispecific inhibitor) recently reported positive data, potentially expanding Zai Lab\u2019s oncology pipeline. ZL-1503 (IL-13\/IL-31R bispecific inhibitor) for moderate-to-severe atopic dermatitis is set to progress to global Phase I clinical trials.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025050801605.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025050801605.\"><\/object><a id=\"wp-block-file--media-570a902f-d1e4-4301-a483-51e10a28df1b\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025050801605.pdf\">2025050801605<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2025050801605.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-570a902f-d1e4-4301-a483-51e10a28df1b\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q1 2025 financial report&#8230;<\/p>\n","protected":false},"author":1,"featured_media":33105,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,869,868,413],"class_list":["post-33103","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-hkg-9688","tag-nasdaq-zlab","tag-zai-lab"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zai Lab Reports Q1 2025 Revenue Growth and Pipeline Progress - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q1 2025 financial report alongside recent product highlights and corporate updates. Total revenues for the quarter stood at USD 106.5 million, marking a 22% year-on-year (YOY) increase at constant exchange rates. The company also reported a significant improvement in operating loss, which declined by 20% YOY to USD 56.3 million, remaining on track to achieve profitability by the fourth quarter of 2025. Research and development (R&amp;D) expenses were USD 60.7 million. As of March 31, 2025, cash and cash equivalents, short-term investments, and current restricted cash totaled USD 857.3 million.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33103\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zai Lab Reports Q1 2025 Revenue Growth and Pipeline Progress\" \/>\n<meta property=\"og:description\" content=\"China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q1 2025 financial report alongside recent product highlights and corporate updates. Total revenues for the quarter stood at USD 106.5 million, marking a 22% year-on-year (YOY) increase at constant exchange rates. The company also reported a significant improvement in operating loss, which declined by 20% YOY to USD 56.3 million, remaining on track to achieve profitability by the fourth quarter of 2025. Research and development (R&amp;D) expenses were USD 60.7 million. As of March 31, 2025, cash and cash equivalents, short-term investments, and current restricted cash totaled USD 857.3 million.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33103\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-09T06:44:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-09T06:44:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0912.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33103#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33103\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zai Lab Reports Q1 2025 Revenue Growth and Pipeline Progress\",\"datePublished\":\"2025-05-09T06:44:20+00:00\",\"dateModified\":\"2025-05-09T06:44:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33103\"},\"wordCount\":275,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33103#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0912.webp\",\"keywords\":[\"Finanical Reports\",\"HKG: 9688\",\"NASDAQ: ZLAB\",\"Zai Lab\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33103#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33103\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33103\",\"name\":\"Zai Lab Reports Q1 2025 Revenue Growth and Pipeline Progress - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33103#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33103#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0912.webp\",\"datePublished\":\"2025-05-09T06:44:20+00:00\",\"dateModified\":\"2025-05-09T06:44:21+00:00\",\"description\":\"China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q1 2025 financial report alongside recent product highlights and corporate updates. Total revenues for the quarter stood at USD 106.5 million, marking a 22% year-on-year (YOY) increase at constant exchange rates. The company also reported a significant improvement in operating loss, which declined by 20% YOY to USD 56.3 million, remaining on track to achieve profitability by the fourth quarter of 2025. Research and development (R&D) expenses were USD 60.7 million. As of March 31, 2025, cash and cash equivalents, short-term investments, and current restricted cash totaled USD 857.3 million.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33103#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33103\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33103#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0912.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/0912.webp\",\"width\":1080,\"height\":608,\"caption\":\"Zai Lab Reports Q1 2025 Revenue Growth and Pipeline Progress\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33103#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zai Lab Reports Q1 2025 Revenue Growth and Pipeline Progress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zai Lab Reports Q1 2025 Revenue Growth and Pipeline Progress - Insight, China&#039;s Pharmaceutical Industry","description":"China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q1 2025 financial report alongside recent product highlights and corporate updates. Total revenues for the quarter stood at USD 106.5 million, marking a 22% year-on-year (YOY) increase at constant exchange rates. The company also reported a significant improvement in operating loss, which declined by 20% YOY to USD 56.3 million, remaining on track to achieve profitability by the fourth quarter of 2025. Research and development (R&D) expenses were USD 60.7 million. As of March 31, 2025, cash and cash equivalents, short-term investments, and current restricted cash totaled USD 857.3 million.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33103","og_locale":"en_US","og_type":"article","og_title":"Zai Lab Reports Q1 2025 Revenue Growth and Pipeline Progress","og_description":"China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q1 2025 financial report alongside recent product highlights and corporate updates. Total revenues for the quarter stood at USD 106.5 million, marking a 22% year-on-year (YOY) increase at constant exchange rates. The company also reported a significant improvement in operating loss, which declined by 20% YOY to USD 56.3 million, remaining on track to achieve profitability by the fourth quarter of 2025. Research and development (R&D) expenses were USD 60.7 million. As of March 31, 2025, cash and cash equivalents, short-term investments, and current restricted cash totaled USD 857.3 million.","og_url":"https:\/\/flcube.com\/?p=33103","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-09T06:44:20+00:00","article_modified_time":"2025-05-09T06:44:21+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0912.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33103#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33103"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zai Lab Reports Q1 2025 Revenue Growth and Pipeline Progress","datePublished":"2025-05-09T06:44:20+00:00","dateModified":"2025-05-09T06:44:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33103"},"wordCount":275,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33103#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0912.webp","keywords":["Finanical Reports","HKG: 9688","NASDAQ: ZLAB","Zai Lab"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33103#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33103","url":"https:\/\/flcube.com\/?p=33103","name":"Zai Lab Reports Q1 2025 Revenue Growth and Pipeline Progress - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33103#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33103#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0912.webp","datePublished":"2025-05-09T06:44:20+00:00","dateModified":"2025-05-09T06:44:21+00:00","description":"China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q1 2025 financial report alongside recent product highlights and corporate updates. Total revenues for the quarter stood at USD 106.5 million, marking a 22% year-on-year (YOY) increase at constant exchange rates. The company also reported a significant improvement in operating loss, which declined by 20% YOY to USD 56.3 million, remaining on track to achieve profitability by the fourth quarter of 2025. Research and development (R&D) expenses were USD 60.7 million. As of March 31, 2025, cash and cash equivalents, short-term investments, and current restricted cash totaled USD 857.3 million.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33103#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33103"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33103#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0912.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0912.webp","width":1080,"height":608,"caption":"Zai Lab Reports Q1 2025 Revenue Growth and Pipeline Progress"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33103#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zai Lab Reports Q1 2025 Revenue Growth and Pipeline Progress"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/0912.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33103","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33103"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33103\/revisions"}],"predecessor-version":[{"id":33106,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33103\/revisions\/33106"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33105"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33103"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33103"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33103"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}